Multiple myeloma (MM) is a hematologic malignancy defined by the clonal proliferation of
transformed plasma cells. Despite tremendous advances in the treatment paradigm of MM, a …

Despite several therapeutic advances over the past decade, multiple myeloma (MM)
remains largely incurable, indicating a need for new treatment approaches. Chimeric …

Background BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited
remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary …

BACKGROUND. CAR T cells are a promising therapy for hematologic malignancies. B cell
maturation antigen (BCMA) is a rational target in multiple myeloma (MM). METHODS. We …

Background Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell
therapy has been shown to have activity in patients with relapsed or refractory multiple …

B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due
to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted …

Chimeric antigen receptors (CAR) are fusion proteins containing an antigen-recognition
domain coupled to a T-cell activation domain (eg, CD3ζ [CD247]) and to a costimulatory …

PURPOSE A combination of anti–B-cell maturation antigen (BCMA) and anti-CD19 chimeric
antigen receptor (CAR) T cells induced high response rates in patients with relapsed or …

Despite the high remission rates achieved using T cells bearing a chimeric antigen receptor
(CAR) against hematogical malignancies, there is still a considerable proportion of patients …

Multiple myeloma (MM), a bone marrow–resident hematological malignancy of plasma cells,
has remained largely incurable despite dramatic improvements in patient outcomes in the …